Journal
ANNALS OF BIOMEDICAL ENGINEERING
Volume 45, Issue 1, Pages 164-179Publisher
SPRINGER
DOI: 10.1007/s10439-016-1640-4
Keywords
Additive Manufacturing; 3D printing; Bioprinting; Drug screening; Tissue engineered constructs
Categories
Funding
- National Cancer Institute of the National Institutes of Health [R01CA163499]
- NATIONAL CANCER INSTITUTE [R01CA163499] Funding Source: NIH RePORTER
- Veterans Affairs [I01BX001957] Funding Source: NIH RePORTER
Ask authors/readers for more resources
2D cell culture and preclinical animal models have traditionally been implemented for investigating the underlying cellular mechanisms of human disease progression. However, the increasing significance of 3D vs. 2D cell culture has initiated a new era in cell culture research in which 3D in vitro models are emerging as a bridge between traditional 2D cell culture and in vivo animal models. Additive manufacturing (AM, also known as 3D printing), defined as the layer-by-layer fabrication of parts directed by digital information from a 3D computer-aided design file, offers the advantages of simultaneous rapid prototyping and biofunctionalization as well as the precise placement of cells and extracellular matrix with high resolution. In this review, we highlight recent advances in 3D printing of tissue engineered constructs that recapitulate the physical and cellular properties of the tissue microenvironment for investigating mechanisms of disease progression and for screening drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available